Share on StockTwits

Analysts at Goldman Sachs lifted their price objective on shares of Illumina (NASDAQ:ILMN) from $184.00 to $187.00 in a research report issued to clients and investors on Tuesday. Goldman Sachs’ price objective would indicate a potential upside of 15.64% from the company’s current price.

In other Illumina news, Director Daniel Bradbury sold 2,100 shares of the company’s stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $159.77, for a total transaction of $335,517.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

ILMN has been the subject of a number of other recent research reports. Analysts at Tigress Financial initiated coverage on shares of Illumina in a research note on Friday. They set a “buy” rating on the stock. Separately, analysts at Credit Suisse reiterated an “outperform” rating on shares of Illumina in a research note on Thursday, July 24th. They now have a $198.00 price target on the stock, up previously from $180.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Illumina in a research note on Thursday, July 24th. They now have a $230.00 price target on the stock, up previously from $190.00. Five research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $172.08.

Shares of Illumina (NASDAQ:ILMN) traded down 1.19% on Tuesday, hitting $159.78. The stock had a trading volume of 144,440 shares. Illumina has a 52-week low of $72.77 and a 52-week high of $185.00. The stock has a 50-day moving average of $172.2 and a 200-day moving average of $158.7. The company has a market cap of $20.864 billion and a P/E ratio of 108.02.

Illumina (NASDAQ:ILMN) last announced its earnings results on Wednesday, July 23rd. The company reported $0.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.50 by $0.07. The company had revenue of $448.00 million for the quarter, compared to the consensus estimate of $426.50 million. During the same quarter last year, the company posted $0.43 earnings per share. Illumina’s revenue was up 29.5% compared to the same quarter last year. Analysts expect that Illumina will post $2.29 EPS for the current fiscal year.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.